Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report-Reference-Cited by-同舟云学术

Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report

Published:2021-02 Issue:2 Volume:110 Page:584-593
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Parrott Neil,Suarez-Sharp Sandra,Kesisoglou Filippos,Pathak Shriram M.,Good David,Wagner Christian,Dallmann André,Mullin James,Patel Nikunjkumar,Riedmaier Arian Emami,Mitra Amitava,Raines Kimberly,Butler James,Kakhi Maziar,Li Min,Zhao Yang,Tsakalozou Eleftheria,Flanagan Talia,Dressman Jennifer,Pepin Xavier

Funder

Center of Excellence in Regulatory Science and Innovation

US Food & Drug Administration

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference38 articles.

1. Challenges and opportunities for patient centric drug product design: industry perspectives;Burke;Pharm Res,2019

2. Dissolution and translational modeling strategies enabling patient-centric drug product development: the M-CERSI workshop summary report;Abend;AAPS J,2018

3. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in Vitro/In Vivo Correlations;FDA,1997

4. Guideline on Quality of Oral Modified Release Products;EMA,2014

5. Applications of in vitro-in vivo correlations in generic drug development: case studies;Kaur;AAPS J,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Drug Development ( MIDD ) Regarding Regulatory Requirements and Thinking;Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0;2024-06-21

2. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report;Molecular Pharmaceutics;2024-04-11

3. Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling;The AAPS Journal;2024-04-04

4. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products;Molecular Pharmaceutics;2023-10-30

5. Biopharmaceutics Risk Assessment—Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions;The AAPS Journal;2023-07-27